Here’s what you should know:
1. Acute and recurrent diabetic gastroparesis primarily affects women. Approximately 80 percent of gastroparesis sufferers are women.
2. Existing oral treatments are ineffective during an acute flare. Evoke created its nasal spray as an treatment for those flare-ups.
3. Evoke President and CEO Dave Gonyer said, “We believe that Gimoti can make an important difference in the lives of these patients and we look forward to FDA approval.”
4. The company expects a decision from the FDA by around August.
More articles on gastroenterology:
Tenet shakes up its board again & more — 9 ASC company key notes
7 outpatient spine stories — June 4, 2018
ASC supply chain tip of the day: Explore purchasing in a low measure
